Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion
- PMID: 8382511
- PMCID: PMC1968269
- DOI: 10.1038/bjc.1993.99
Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion
Abstract
Single-chain urokinase-type plasminogen activator (pro-uPA) is bound to a specific surface receptor on ovarian cancer HOC-I cells that is incompletely saturated. Saturation of uncovered receptors by uPA polypeptides with intact amino-terminal fragment (ATF) derived from pro-uPA by limited proteolysis (human leucocyte elastase [HLE] or V8 protease) has been studied. HOC-I cells preferentially invaded reconstituted basement membranes in a time- and plasminogen-dependent manner. This process was inhibitable by preincubation with uPA polypeptides in the medium at levels which suggested that complete saturation of cell surface uPA receptors occurred. This result indicates that occupation of uPA receptors by enzymatically inactive uPA fragments or prevention of rebinding of pro-uPA synthesised by tumour cells to the receptors specifically reduces the invasion of the tumour cells through basement membranes in vitro.
Similar articles
-
cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.DNA Cell Biol. 2001 May;20(5):297-305. doi: 10.1089/104454901750232490. DNA Cell Biol. 2001. PMID: 11410166
-
Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751
-
Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.FEBS Lett. 1998 Oct 30;438(1-2):101-5. doi: 10.1016/s0014-5793(98)01279-4. FEBS Lett. 1998. PMID: 9821967
-
[Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].Nihon Sanka Fujinka Gakkai Zasshi. 1996 Aug;48(8):623-32. Nihon Sanka Fujinka Gakkai Zasshi. 1996. PMID: 8808830 Review. Japanese.
-
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?Eur J Surg Oncol. 2017 Feb;43(2):252-257. doi: 10.1016/j.ejso.2016.06.002. Epub 2016 Jun 20. Eur J Surg Oncol. 2017. PMID: 27345498 Review.
Cited by
-
Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.Clin Exp Metastasis. 1999 Feb;17(1):77-85. doi: 10.1023/a:1026470417680. Clin Exp Metastasis. 1999. PMID: 10390151
-
Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.J Virol. 2003 Nov;77(21):11491-8. doi: 10.1128/jvi.77.21.11491-11498.2003. J Virol. 2003. PMID: 14557634 Free PMC article.
-
Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.Br J Cancer. 1995 Nov;72(5):1131-7. doi: 10.1038/bjc.1995.476. Br J Cancer. 1995. PMID: 7577458 Free PMC article.
-
Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.Clin Exp Metastasis. 1995 Jul;13(4):296-302. doi: 10.1007/BF00133485. Clin Exp Metastasis. 1995. PMID: 7606892
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous